<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01616381</url>
  </required_header>
  <id_info>
    <org_study_id>SUS2011DIKE01</org_study_id>
    <secondary_id>2011-002829-21</secondary_id>
    <nct_id>NCT01616381</nct_id>
  </id_info>
  <brief_title>Sildenafil Versus Placebo in Chronic Heart Failure</brief_title>
  <acronym>SilHF</acronym>
  <official_title>Sildenafil in Heart Failure (SilHF); An Investigator Initiated Multinational Randomized Controlled Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helse Stavanger HF</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Helse Stavanger HF</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This protocol describes a 2-arm randomised controlled pilot study assessing the tolerance,&#xD;
      safety and efficacy of sildenafil compared to control. The hypothesis is that sildenafil will&#xD;
      be well tolerated and efficacious in patients with chronic heart failure (NYHA class II and&#xD;
      III) with evidence of systolic dysfunction (EF â‰¤40 %) and secondary pulmonary hypertension&#xD;
      (SPAP &gt;40mmHg).&#xD;
&#xD;
      Patients that satisfy the inclusion criteria will be randomized to sildenafil (40mg x 3) or&#xD;
      placebo therapy for 6 months in a 2:1 blinded fashion. The placebo group will be compared to&#xD;
      the active therapy group and analysed for differences in the main study end-points Patient&#xD;
      Global Assessment and 6-Minute Walk Test.&#xD;
&#xD;
      The study will also assess safety, tolerability, symptoms and quality of life.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is estimated that 2-3 % of the adult population suffers from heart failure (HF) and the&#xD;
      prevalence is increasing. The European Society of Cardiology (ESC) represents countries with&#xD;
      a population &gt; 1,1 billion, and it is estimated that approximately 30 million patients have&#xD;
      HF in these 53 countries. Heart failure is particularly prevalent in the elderly population&#xD;
      and represents a major burden for both patients and the health services. HF is present in&#xD;
      over 10% of patients admitted to hospital and accounts for ~ 2% of national health expenses.&#xD;
      Approximately 50% of these costs are related to hospitalisation.&#xD;
&#xD;
      Despite optimal non-pharmacological, pharmacological and device therapy, the morbidity among&#xD;
      HF patients is high with symptoms such as dyspnoea and fatigue that reduce quality of life.&#xD;
      Following diagnosis approximately 50% are dead after 4 years. Forty percent of patients&#xD;
      admitted to hospital with HF are either dead or rehospitalised within one year.&#xD;
&#xD;
      During the last decade, PDE5-inhibitors have been evaluated as a potential treatment for&#xD;
      heart failure (see scientific rationale and reference). However, these investigations have&#xD;
      been small and there is still limited data. Trials assessing the acute effects of&#xD;
      PDE5-inhibition in patients with symptomatic HF due to systolic dysfunction have been&#xD;
      performed primarily with sildenafil. Due to the short half-life of sildenafil the drug is&#xD;
      administered 3 times daily when studying its chronic effects.&#xD;
&#xD;
      Previous studies have evaluated the 50 mg dose acutely and 50 mg 3 times daily during&#xD;
      short-term chronic studies. Importantly, there is considerable off-label use of sildenafil in&#xD;
      symptomatic heart failure patients in most European countries.&#xD;
&#xD;
      Revatio is currently licenced for pulmonary hypertension group 1. The dosing scheme is 20mg x&#xD;
      3. However, we suggest targeting a higher dose to achieve optimal clinical benefit in&#xD;
      patients with heart failure and moderate congestion. As mentioned above most of the clinical&#xD;
      literature in patients with symptomatic heart failure has been done using the 50mg x 3&#xD;
      regimen. However, it is believed that in the proposed study using 40mg x 3 should be equally&#xD;
      efficacious. There is already considerable experience using this dosage scheme in heart&#xD;
      failure patients locally.&#xD;
&#xD;
      The hemodynamic profile of PDE-5 inhibitors is favourable with reduction in filling&#xD;
      pressures, both systemic and pulmonary, vascular resistance accompanied by improvement in&#xD;
      symptoms and submaximal and peak exercise performance. This pilot study will evaluate the use&#xD;
      of the PDE5-inhibitor sildenafil in patients with heart failure, systolic dysfunction and&#xD;
      documented secondary pulmonary hypertension.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">March 2013</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient Global Assessment</measure>
    <time_frame>Baseline, 8 weeks, 24 weeks</time_frame>
    <description>Analysis of change from baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Six minute walk test</measure>
    <time_frame>Baseline, 8 weeks, 24 weeks</time_frame>
    <description>Analysis of change from baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QoL) evaluation by EuroQol5D</measure>
    <time_frame>Baseline, 8 weeks and 24 weeks</time_frame>
    <description>Analysis of change from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kansas City Questionaire</measure>
    <time_frame>Baseline, 8 weeks and 24 weeks</time_frame>
    <description>Analysis of change from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New York Heart Association (NYHA) function class</measure>
    <time_frame>Baseline, 8 weeks, 16 weeks and 24 weeks</time_frame>
    <description>Analysis of change from baseline.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Heart Failure</condition>
  <condition>Pulmonary Hypertension</condition>
  <arm_group>
    <arm_group_label>Sildenafil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sildenafil tablets 40 mg x 3 daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablet x 3 daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sildenafil</intervention_name>
    <description>PDE-5 Inhibitor</description>
    <arm_group_label>Sildenafil</arm_group_label>
    <other_name>Revatio</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for sildenafil 40mg x 3 daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men and women&#xD;
&#xD;
          2. 18 - 80 years of age.&#xD;
&#xD;
          3. Outpatients with chronic HF. NYHA class II-III on optimal treatment in sinus rhythm or&#xD;
             atrial fibrillation&#xD;
&#xD;
          4. LVEF &lt; 40% measured during the past 12 months&#xD;
&#xD;
          5. SPAP &gt; 40mmHg using echocardiography&#xD;
&#xD;
          6. 6MWTD &lt; 400 meters&#xD;
&#xD;
          7. NT-pro BNP &gt; 400 pg/ml or BNP &gt;100 pg/ml, measured during the past 12 months&#xD;
&#xD;
          8. Receiving optimal therapy, including diuretic, ACE-inhibitor, ARB, beta-blocker and&#xD;
             aldosterone antagonist. Doses of all medication should be unchanged during the last 30&#xD;
             days before inclusion.&#xD;
&#xD;
          9. ICDs and CRTs (CRT-P, CRT-D) are permitted. Implantation should have been performed at&#xD;
             &gt; 3 months before inclusion to the trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Acute Coronary Syndrome, including myocardial infarction, or coronary angiography,&#xD;
             with or without intervention, within the last 3 months&#xD;
&#xD;
          2. Stroke within the last 3 months&#xD;
&#xD;
          3. Planned coronary angiography or planned device-implantation&#xD;
&#xD;
          4. Moderate to severe obstructive valve disease&#xD;
&#xD;
          5. Documented episodes of sustained ventricular tachycardia&#xD;
&#xD;
          6. Oral nitrate therapy or frequent use of sublingual nitrate&#xD;
&#xD;
          7. Concomitant disease which interfere with assessment of dyspnoea , severe COPD, asthma,&#xD;
             restrictive lung disease, severe obesity&#xD;
&#xD;
          8. Anemia (hemoglobin &lt; 10g/dL)&#xD;
&#xD;
          9. Uncontrolled hypertension ( SBP &gt;160 mmHg and / or DBP &gt; 90 mmHg)&#xD;
&#xD;
         10. Symptomatic or orthostatic hypotension or systolic blood pressure &lt; 90 mmHg&#xD;
&#xD;
         11. Clinically important renal dysfunction (GFR &lt; 40m ml/min)&#xD;
&#xD;
         12. Women with child-bearing potential&#xD;
&#xD;
         13. Use of&#xD;
&#xD;
             i) alpha-1 antagonist: doxazosin&#xD;
&#xD;
             ii) CYP3A4 inhibitors: erytromycin, ritonavir, sakinovir, itraconazole, ketoconazole&#xD;
&#xD;
             iii) CYP3A4-inducers: rifampicin&#xD;
&#xD;
             iv) Any calcium channel blockers&#xD;
&#xD;
         14. Retinitis pigmentosa, previous diagnosis of NAION (non-arteritic ischemic&#xD;
             optic-neuropathy), unexplained visual disturbance.&#xD;
&#xD;
         15. Sickle cell anemia, multiple myeloma, leukemia or penile anatomic deformities&#xD;
             (angulation, cavernosal fibrosis, Peyronie's disease) that increases the risk of&#xD;
             priapism.&#xD;
&#xD;
         16. Hepatic failure.&#xD;
&#xD;
         17. Drug and alcohol abuse which precludes compliance with the protocol.&#xD;
&#xD;
         18. Inability to understand or sign the written informed consent form of the study,&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth Dickstein, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helse Stavanger HF</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lady Davis Carmel Medical CEnter</name>
      <address>
        <city>Haifa</city>
        <zip>34362</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center</name>
      <address>
        <city>Petah Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Donato Hospital</name>
      <address>
        <city>Milano</city>
        <zip>20097</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stavanger University Hospital</name>
      <address>
        <city>Stavanger</city>
        <state>Rogaland</state>
        <zip>4011</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Castle Hill Hospital</name>
      <address>
        <city>Hull</city>
        <zip>HU16 5JQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern General Hospital</name>
      <address>
        <city>Sheffield</city>
        <zip>S5 7AU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
    <country>Italy</country>
    <country>Norway</country>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Cooper TJ, Guazzi M, Al-Mohammad A, Amir O, Bengal T, Cleland JG, Dickstein K. Sildenafil in Heart failure (SilHF). An investigator-initiated multinational randomized controlled clinical trial: rationale and design. Eur J Heart Fail. 2013 Jan;15(1):119-22. doi: 10.1093/eurjhf/hfs152. Epub 2012 Oct 24.</citation>
    <PMID>23097067</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>June 1, 2012</study_first_submitted>
  <study_first_submitted_qc>June 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2012</study_first_posted>
  <last_update_submitted>May 4, 2018</last_update_submitted>
  <last_update_submitted_qc>May 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sildenafil Citrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

